EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Aurora Kinases as Essential Cell‐Cycle Regulators to Deliver Multi‐Stage Antimalarials Against Plasmodium Falciparum

Henrico Langeveld, Keletso Maepa, Marché Maree, Jessica L Thibaud, Nicolaas Salomane, Rosie Bridgwater, Mufuliat T Famodimu, Luiz C Godoy, Charisse Flerida A Pasaje, Nonlawat Boonyalai, Mariana Laureano de Souza, Justin Fong und 12 weitere

Angewandte Chemie International Edition · 15.12.2025 · 64 (51)

DOI: 10.1002/anie.202518493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 23.10.2025. Verfasst von Henrico Langeveld und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Genetics and Microbiology, Hatfield, Pretoria, 0028, South Africa. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Protein Kinase Inhibitors, Aurora Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI MRC Career Development Award, South African Medical Research Council, Institute for Sustainable Malaria Control, University of Pretoria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kinases play critical roles in the development and adaptation of Plasmodium falciparum and present novel opportunities for chemotherapeutic intervention. Mitotic kinases that regulate the proliferation of the parasites by controlling nuclear division, segregation, and cytokinesis. We evaluated the potential of human Aurora kinase (Aur) inhibitors to prevent P. falciparum development by targeting members of the Aurora‐related kinase (Ark) family in this parasite. Several human AurB inhibitors exhibited multistage potency (< 250 nM) against all proliferative stages of parasite development, including asexual blood stages, liver schizonts, and male gametes. The most potent compounds, hesperadin, TAE684, and AT83, exhibited > 1000x selectivity towards the parasite. Importantly, we identified Pf Ark1 as the principal vulnerable Ark family member, with specific inhibition of Pf Ark1 as the primary target for hesperadin. Hesperadin's whole‐cell and protein activity validates it as a unique Pf Ark1 tool compound. Inhibition of Pf Ark1 results in the parasite's inability to complete mitotic processes, presenting with unsegregated, multi‐lobed nuclei caused by aberrant microtubule organization. This suggests Pf Ark1 is the main Aur mitotic kinase in proliferative stages of Plasmodium , characterized by bifunctional AurA and B activity. This paves the way for drug‐discovery campaigns based on hesperadin targeting Pf Ark1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumAntimalarialsProtein Kinase InhibitorsAurora KinasesHumansCell Cycle

Stichwörter der Autor:innen

Antimalarial drug discoveryAnti‐cancer inhibitorsAurora kinaseCell cycle regulationPlasmodium

Substanzen

AntimalarialsProtein Kinase InhibitorsAurora Kinases

Autor:innen und Institutionen

  • Department of Biochemistry, Genetics and Microbiology, Hatfield, Pretoria, 0028, South Africa.
  • Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria, 0028, South Africa.
  • South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, Cape Town, 77…
  • Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, Cape Town, 7701, South Africa.
  • Department of Biochemistry, Stellenbosch University, Stellenbosch, 7602, South Africa.
  • LSHTM Malaria Centre, London School of Hygiene and Tropical Medicine, London, UK.

ORCID-Profile: Lyn-Marié Birkholtz

Förderung

  • UKRI MRC Career Development Award
  • South African Medical Research Council
  • Institute for Sustainable Malaria Control, University of Pretoria
  • Medicines for Malaria Venture
  • South African National Research Foundation
  • Gates Foundation

Zitieren

APA

Langeveld, H., Maepa, K., Maree, M., Thibaud, J. L., Salomane, N., Bridgwater, R., Famodimu, M. T., Godoy, L. C., Pasaje, C. F. A., Boonyalai, N., de Souza, M. L., Fong, J., Rabie, T., van der Watt, M., Theart, R. P., Ghidelli-Disse, S., Niles, J. C., Lee, M. C. S., Winzeler, E. A., …, & Birkholtz, L. M. (2025). Targeting Aurora Kinases as Essential Cell‐Cycle Regulators to Deliver Multi‐Stage Antimalarials Against Plasmodium Falciparum. Angewandte Chemie International Edition, 64(51). https://doi.org/10.1002/anie.202518493

Vancouver

Langeveld H, Maepa K, Maree M, Thibaud JL, Salomane N, Bridgwater R, et al. Targeting Aurora Kinases as Essential Cell‐Cycle Regulators to Deliver Multi‐Stage Antimalarials Against Plasmodium Falciparum. Angewandte Chemie International Edition. 2025;64(51). doi:10.1002/anie.202518493

BibTeX
@article{Langeveld2025,
  author = {Langeveld, Henrico and Maepa, Keletso and Maree, Marché and Thibaud, Jessica L and Salomane, Nicolaas and Bridgwater, Rosie and Famodimu, Mufuliat T and Godoy, Luiz C and Pasaje, Charisse Flerida A and Boonyalai, Nonlawat and de Souza, Mariana Laureano and Fong, Justin and Rabie, Tayla and van der Watt, Mariëtte and Theart, Rensu P and Ghidelli-Disse, Sonja and Niles, Jacquin C and Lee, Marcus C S and Winzeler, Elizabeth A and Delves, Michael J and Chibale, Kelly and Wicht, Kathryn J and Coulson, Lauren B and Birkholtz, Lyn-Marié},
  title = {Targeting Aurora Kinases as Essential Cell‐Cycle Regulators to Deliver Multi‐Stage Antimalarials Against Plasmodium Falciparum},
  journal = {Angewandte Chemie International Edition},
  year = {2025},
  volume = {64},
  number = {51},
  doi = {10.1002/anie.202518493}
}
Kostenlos starten →